Michael Head
Optometrist · Hurst, TXNPI 1174873574
Payments from drug & device makers
Across 193 payments — averaging $33.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Alcon$883
- Glaukos Corporation$666
- Novartis$494
- Bausch & Lomb Americas Inc.$388
- Notal Vision, Inc.$387
- plus $2K from 19 others
Across 3 payments — averaging $13.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$39
What the payments were for
- Speaking & faculty fees$3876%
- Food & beverage$6,01194%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 54 | $1,163 |
| Alcon | 27 | $883 |
| Glaukos Corporation | 4 | $666 |
| Novartis | 17 | $494 |
| Bausch & Lomb Americas Inc. | 14 | $388 |
| Notal Vision, Inc. | 1 | $387 |
| Dompe US, Inc. | 8 | $354 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 11 | $314 |
| Biotissue Holdings Inc. | 7 | $281 |
| Rxsight Inc | 5 | $279 |
| Shire North American Group Inc | 6 | $218 |
| Sun Pharmaceutical Industries Inc. | 9 | $198 |
| Oyster Point Pharma, Inc. | 2 | $157 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $147 |
| Tarsus Pharmaceuticals, Inc. | 6 | $131 |
| Sight Sciences, Inc. | 5 | $91 |
| Aerie Pharmaceuticals, Inc. | 4 | $76 |
| Carl Zeiss Meditec USA, Inc. | 1 | $40 |
| Eyevance Pharmaceuticals LLC | 2 | $25 |
| Amgen | 1 | $23 |
| Ocular Therapeutix, Inc. | 1 | $21 |
| Eyepoint US, Inc. | 1 | $19 |
| NEW World Medical,inc. | 1 | $16 |
| Tearlab Corp | 1 | $15 |
| Kala Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iDoseTR$299
- Clareon$248
- XIIDRA$243
- Oxervate$235
- DURYSTA$221
- RXSIGHT CONTACT LENS$149
- RXSIGHT INJECTOR CARTRIDGE$149
- RXSIGHT INJECTOR HANDPIECE$149
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$149
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$149
- ORA$124
- iStent infinite Trabecular Micro-Bypass System Model iS3$123
- Radius XR$123
- iS3-iStent infiniteTrabecular Micro-Bypass System Model iS3$123
- TRAVATAN Z$121
- TYRVAYA$119
- Rocklatan$103
- Rhopressa$103
- SIMBRINZA$103
How this compares
$6,398 in reported general payments places this provider in the 90th percentile of 4,315 optometrist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 172 | $99,864 |
| RestasisCyclosporine | 83 | $90,129 |
| XiidraLifitegrast | 36 | $50,523 |
| Cyclosporine | 49 | $13,625 |
| Travoprost | 105 | $13,320 |
| CombiganBrimonidine Tartrate/Timolol | 32 | $10,978 |
| VyzultaLatanoprostene Bunod | 17 | $10,308 |
| Latanoprost | 854 | $8,947 |
| Prednisolone Acetate | 199 | $8,611 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 47 | $7,384 |
| Brinzolamide | 26 | $5,616 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 15 | $5,585 |
| Famciclovir | 42 | $3,630 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 268 | $2,769 |
| ValacyclovirValacyclovir Hcl | 31 | $2,672 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $1,163 | $200,971287 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $388 | $60,83253 claims |
| AlconSimbrinza | $883 | $5,58515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,315 optometrist providers in Texas.
Other optometrist in Hurst
- Tiffany HuynhHouston$3.2M
- Bridgitte LeeHouston$3M
- Bryan FrazierTyler$1.4M
- Derek CunninghamAustin$940K
- Wendy ChungKaty$900K
- Phillip BrunsonHouston$766K
- Claudio LagunasHouston$644K
- Ashley Wallace-TuckerHouston$568K
- Mina VanrachackSan Antonio$553K
- Luis RojasMcKinney$309K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.